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ST elevation is a pivotal finding in Brugada syndrome. There
has been debate for a long time as to whether the ST elevation
results from a depolarization abnormality or a repolarization
abnormality.1 According to the repolarization abnormality
hypothesis, the pathophysiology of Brugada syndrome is
due to a morphologic change of the epicardial action potential
and transmural dispersion of the repolarization. On the other
hand, according to the depolarization abnormality hypothe-
sis, the ST elevation is due to a voltage gradient induced
by delayed epicardial conduction. Delayed potentials, which
are a marker of a depolarization abnormality, usually cannot
be recorded on the endocardial surface but can be recorded on
the ventricular epicardium in patients with Brugada syn-
drome.2 In 2011, Nademanee and colleagues3 reported that
epicardial mapping in patients with frequent ventricular
fibrillation (VF) episodes revealed abnormal delayed poten-
tials existing on the epicardial surface of the right ventricular
outflow tract (RVOT). Radiofrequency catheter ablation of
the area with abnormal potentials eliminated the typical
Brugada-type ST elevation and prevented the occurrence of
VF.3–5 The results of ablation have indicated that ST
elevation and arrhythmogenicity in high-risk patients are
closely associated with epicardial abnormal potentials.
Epicardial mapping and ablation are invasive methods and
their application is now limited to high-risk patients with
recurrent VF episodes.3–6 However, in asymptomatic
patients with Brugada syndrome, the existence and role of
delayed potentials in the appearance of a type
1 electrocardiogram (ECG) have not been reported. We
here report the results of epicardial mapping in anKEYWORDS Asymptomatic; Brugada syndrome; Catheter ablation; Epicar-
dial mapping; Open chest surgery
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received enucleation surgery of an intracardiac tumor.Case report
A 55-year-old man in whom a Brugada-type ECG was
detected in a medical check-up was referred to our hospital
in 2002. He had not experienced any syncopal episodes
and did not have a family history of sudden death. His
ECG was a spontaneous type 1 ECG (Figure 1A), and late
potentials recorded by signal-averaged electrocardiography
were positive. Programmed electrical stimulation (PES)
from the right ventricular apex and RVOT with triple extra-
stimuli (coupling interval 180 ms) did not induce any
VF. The effective refractory periods were 230 ms at the right
ventricular apex and 220ms in the RVOT (basic cycle length:
600 ms). Analysis of the SCN5A gene showed that the patient
did not have any mutations. Although he had a spontaneous
type 1 ECG, we considered from the clinical characteristics
and results of PES that he was at low risk for VF, and he
was followed in the outpatient clinic once a year.
An ECG recorded in the outpatient clinic in August 2015
revealed frequent premature ventricular contractions (PVCs)
(Figure 1A), but the patient did not experience any symp-
toms. An ambulatory ECG showed that the occurrence of
monofocal PVCs was 10,929 beats/day (10% of the total
beats) and that there were no couplets or salvos of PVCs.
The occurrence of PVCs did not change during follow-up,
and a re-evaluation of the risk in this patient was planned.
Contrast-enhanced computed tomography showed no right
ventricle (RV) abnormalities but revealed an intracardiac tu-
mor on the intra-atrial septum of the left atrium, suggesting
that it was an atrial myxoma. RV endocardial substrate map-
ping and ablation for PVCs were planned before the cardiac
surgery to eliminate the possibility of any lethal arrhythmias
during the perioperative period. After informed consent was
obtained, 2 vascular sheaths were placed in the right femoral
vein for a quadripolar catheter and an 8F irrigated ablation
catheter (NaviStar ThermoCool SmartTouch, Biosense
Webster, Diamond Bar, CA) with a D curve to be placed in
the RV. Then endocardial RV voltage mapping wasn access article
/).
https://doi.org/10.1016/j.hrcr.2019.07.003
KEY TEACHING POINTS
 Epicardial mapping was done in a patient with
sporadic and entirely asymptomatic Brugada
syndrome.
 Multiple abnormal potentials were recorded on the
right ventricle epicardium, especially from below
the pulmonary artery valve to above the tricuspid
annulus.
 The electrocardiogram was normalized after
ablation of the abnormal epicardial potentials.
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(CARTO 3, Biosense Webster, Diamond Bar, CA), and the
target PVCs were ablated by a pace mapping and activation
mapping technique (Figure 2B). The PVCs disappeared after
the ablation, but an extensive low-voltage potential region
was found in the RVOT during endocardial mapping
(Figures 1B and 2A). This finding suggested the existence
of an epicardial abnormal substrate.
With permission from Okayama University’s ethics
committee, epicardial mapping was planned at the time of
open chest surgery to resect the cardiac tumor. Epicardial map-
ping was performed using a 7F decapolar catheter (DecaNav,
Biosense Webster, Diamond Bar, CA) before and after infu-
sion of pilsicainide (1 mg/kg). The total mapping points
were 284 before and 292 after the pilsicainide infusion. Mul-
tiple abnormal potentials were found in the RVOTbetween the
region below the pulmonary artery and around the tricuspid
annulus before pilsicainide infusion (Figure 3). The area inFigure 1 A: Typical Brugada-type electrocardiogram (ECG) during sinus rhyth
(PVCs).B: Typical Brugada-type ECG remaining after PVC ablation.C:Normalize
epicardial.which the abnormal potentials were recorded became enlarged
after pilsicainide infusion. Those potentials were ablated using
an 8F irrigated ablation catheter (NaviStar ThermoCool
SmartTouch, Biosense Webster) with a D curve.
After the epicardial ablation, the ECG was normalized
(Figure 1C) and the late potentials were eliminated. The
patient has been free from any symptoms and has not experi-
enced any ventricular arrhythmic events.Discussion
Here we report open chest epicardial mapping in an asymp-
tomatic patient with Brugada syndrome. The patient did not
have any symptoms or a family history of sudden death.
PES failed to induce VF. This asymptomatic sporadic patient
was considered to be at low risk. Open heart surgery was
required for an intra-atrial myxoma that was incidentally
found, and it was decided to perform epicardial mapping
and ablation at the time of surgery. Various abnormal poten-
tials including low-voltage, fragmented, and double or
delayed potentials were found on the epicardial surface
from the RV free wall to the RVOT. The morphologies of
those abnormal potentials were similar to the potentials
previously reported in high-risk patients.3–5 Application of
radiofrequency ablation to the abnormal potentials
eliminated the Brugada-type ST elevation and normalized
the ECG. Our case indicated that abnormal delayed potentials
can exist even in asymptomatic sporadic patients who are
thought to be at low risk.
Epicardial abnormal potentials in patients with Brugada
syndrome were initially recorded through a guidewire in
the conus branch of the right coronary artery. Nagase
and colleagues2 reported that delayed potentials were
recorded in 5 patients (3 patients with VF and 2m before endocardial ablation of frequent premature ventricular contractions
d ECG after epicardial ablation. ABL5 ablation; Endo5 endocardial; Epi5
Figure 2 A:Right ventricle (RV) endocardial mapping and a low-voltage area in the right ventricular outflow tract from the pulmonary artery to tricuspid valve.
B: Late potentials at the ablation site of the targeted premature ventricular contraction (PVC) during sinus rhythm (left) and pre-potentials recorded immediately
before the targeted PVC (right).
Figure 3 Multiple abnormal potentials on the right ventricle recorded by epicardial mapping during open heart surgery. Ao5 aorta; PA5 pulmonary artery;
RVA 5 right ventricular apex; TVA 5 tricuspid valve annulus.
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administration of a sodium channel blocker. PES induced
VF in 2 asymptomatic patients and an asymptomatic pa-
tient died suddenly after 10 years. In 2011, Nademanee
and colleagues3 reported the results of direct epicardial
mapping and radiofrequency catheter ablation in 9 patients
with Brugada syndrome who had recurrent VF episodes.
All of the patients had low-voltage, widening, and frac-
tionated late potentials in the anterior aspect of the
RVOT epicardium. After that report, Brugada and col-
leagues4 reported epicardial mapping and ablation in 14
symptomatic patients with induced VT/VF, and Zhang
and colleagues5 also reported 11 patients with syncope
or VF. Both reports showed abnormal potentials similar
to those in Nademanee’s study.3 Histologic examination
revealed that a reduction in connexin 43, increased intersti-
tial collagen, and replacement of fibrosis occurred in the
RVOT epicardium and that those pathologic changes
generated abnormal potentials.6 Fibrosis in the epicardial
layer causes delayed activation and conduction block at
the epicardium and promotes ST elevation by a current-
to-load mismatch.7
Most of the patients in the previous studies were high-risk
patients who had syncope, VF episodes, or PES-induced VF.
One study included an asymptomatic patient with drug-
induced Brugada syndrome who had atrial fibrillation.7
That patient had longer fractionated potentials than those in
the controls. The present case had a spontaneous type 1
ECG but did not have a family history of sudden death or
PES-induced VF. Direct epicardial mapping and ablation
were performed during open chest surgery and complete
detailed mapping on the epicardial surface of the RV was
achieved. Although there are not sufficient epicardial map-
ping data for asymptomatic patients, the results of the epicar-
dial mapping in the present case showed that the epicardial
fractionated potentials are most likely to be associated withthe generation of ST elevation even in asymptomatic
low-risk patients with Brugada syndrome.
We did not evaluate epicardial repolarization, and the
results presented in this case report therefore cannot deny
the repolarization abnormality hypothesis. A delayed
upstroke of the phase 2 dome in the epicardial action poten-
tial and a concealed phase 2 reentry could also explain the
fractionated potentials.8 Evaluation of repolarization abnor-
malities by using, for example, monophasic action potentials
is needed to determine the mechanism of ST elevation and
arrhythmogenesis in Brugada syndrome.Acknowledgment
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